HER2-positive breast cancer Archives -

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC)

ESMO21: Enhertu brings it’s A game to second-line breast cancer

https://pharmaphorum.com/news/esmo21-enhertu-brings-its-a-game-to-second-line-breast-cancer/

News/ News/ Oncology

MHRA approves Seagen’s oral HER2 drug Tukysa

Phil Taylor HER2-positive breast cancer, MHRA, regulatory approval, Seattle Genetics, tucatinib, UK 0 Comment

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after

MHRA approves Seagen’s oral HER2 drug Tukysa

https://pharmaphorum.com/news/mhra-approves-seagens-oral-her2-drug-tukysa/

News/ News/ Oncology

Roche claims EU okay for Herceptin/Perjeta combination Phesgo

Phil Taylor EU, HER2-positive breast cancer, Oncology, Phesgo, regulatory approval, Roche 0 Comment

Roche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta

Roche claims EU okay for Herceptin/Perjeta combination Phesgo

https://pharmaphorum.com/news/roches-claims-eu-okay-for-herceptin-perjeta-combination-phesgo/

Cancer/ News/ News/ News/ Oncology/ R&D

Puma Biotechnology’s breast cancer drug approved in Europe

Piotr Wnuk breast cancer, HER2-positive breast cancer, Puma Biotechnology 0 Comment

Puma Biotechnology received European Commission (EC) marketing authorisation for Nerlynx (neratinib) in breast cancer, despite earlier European Medicines

Puma Biotechnology’s breast cancer drug approved in Europe

https://pharmaphorum.com/news/ec-approves-puma-breast-cancer-drug/

Market Access/ News/ News/ News/ Oncology

Pfizer wins Herceptin biosimilar approval in Europe

Piotr Wnuk biosimilar, breast cancer, European Commission, HER2-positive breast cancer, herceptin, Oncology, Pfizer, Trazimera 0 Comment

European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first

Pfizer wins Herceptin biosimilar approval in Europe

https://pharmaphorum.com/news/herceptin-biosimilar-european-approval/

Market Access/ News/ News/ News/ Oncology

Roche’s Perjeta combo approved in Europe for early breast cancer

Linda Banks breast cancer, cancer, cancer drug, HER2-positive breast cancer, Oncology, Perjeta 0 Comment

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.

Roche’s Perjeta combo approved in Europe for early breast cancer

https://pharmaphorum.com/news/roches-perjeta-approved-early-breast-cancer/

Trending

HER2-positive breast cancer

Login